64 CuCl 2 PET/CT in Prostate Cancer Relapse.

Autor: Piccardo A; Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy arnoldo.piccardo@galliera.it., Paparo F; Department of Radiology, E.O. Galliera Hospital, Genoa, Italy., Puntoni M; Clinical Trial Unit, Office of the Scientific Director, Galliera Hospital, Genoa, Italy., Righi S; Medical Physics Department, E.O. Galliera Hospital, Genoa, Italy., Bottoni G; Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy., Bacigalupo L; Department of Radiology, E.O. Galliera Hospital, Genoa, Italy., Zanardi S; Department of Oncology, E.O. Galliera Hospital, Genoa, Italy., DeCensi A; Department of Oncology, E.O. Galliera Hospital, Genoa, Italy., Ferrarazzo G; Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy., Gambaro M; Medical Physics Department, E.O. Galliera Hospital, Genoa, Italy., Ruggieri FG; Department of Radiotherapy, E.O. Galliera Hospital, Genoa, Italy., Campodonico F; Department of Urology, E.O. Galliera Hospital, Genoa, Italy., Tomasello L; Department of Oncology, IRCCS San Martino IST, University of Genoa, Genoa, Italy., Timossi L; Department of Urology, E.O. Evangelico Internazionale Hospital, Genoa, Italy., Sola S; Department of Histopathology, E.O. Galliera Hospital, Genoa, Italy; and., Lopci E; Department of Nuclear Medicine, Humanitas Research Hospital, Milano, Italy., Cabria M; Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2018 Mar; Vol. 59 (3), pp. 444-451. Date of Electronic Publication: 2017 Sep 08.
DOI: 10.2967/jnumed.117.195628
Abstrakt: Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of 64 CuCl 2 in humans and to assess the ability of 64 CuCl 2 PET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent 64 CuCl 2 PET/CT, 18 F-choline PET/CT, and multiparametric MRI within 15 d of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available; clinical or laboratory response; and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions, and radiation dosimetry of 64 CuCl 2 were evaluated. Results: From a dosimetric point of view, an administered dose of 200 MBq for 64 CuCl 2 translated into a 5.7-mSv effective dose. Unlike 18 F-choline, 64 CuCl 2 was not excreted or accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum 64 CuCl 2 uptake at the sites of PCa relapse was observed 1 h after tracer injection. In our cohort, 64 CuCl 2 PET/CT proved positive in 41 of 50 patients, with an overall DR of 82%. The DRs of 18 F-choline PET/CT and multiparametric MRI were 56% and 74%, respectively. The difference between the DRs of 64 CuCl 2 PET/CT and 18 F-choline PET/CT was statistically significant ( P < 0.001). Interestingly, on considering prostate-specific antigen (PSA) value, 64 CuCl 2 PET/CT had a higher DR than 18 F-choline PET/CT in patients with a PSA of less than 1 ng/mL. Conclusion: The biodistribution of 64 CuCl 2 is more suitable than that of 18 F-choline for exploring the pelvis and prostatic bed. The 64 CuCl 2 effective dose is like those of other established PET tracers. In patients with biochemical relapse and a low PSA level, 64 CuCl 2 PET/CT shows a significantly higher DR than 18 F-choline PET/CT.
(© 2018 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze: MEDLINE
Externí odkaz: